Research programme: dihydroorotate dehydrogenase inhibitors - Chelsea Therapeutics

Drug Profile

Research programme: dihydroorotate dehydrogenase inhibitors - Chelsea Therapeutics

Alternative Names: DHODH inhibitors - Chelsea Therapeutics; I-3D project

Latest Information Update: 27 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Active Biotech
  • Developer Lundbeck A/S
  • Class Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Autoimmune disorders; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 24 Jun 2014 Chelsea Therapeutics has been acquired and merged into Lundbeck A/S
  • 08 Apr 2008 Chelsea Therapeutics International acquires global rights to I-3D from Active Biotech
  • 02 Nov 2006 Preclinical trials in Rheumatoid arthritis in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top